Skip to main content

Upcoming holiday closures 

Quest Patient Service Centers will be closed on Friday, July 3 and Saturday, July 4, 2026, in observance of Independence Day, and to give our frontline team the time to recharge. Don't let the holiday interrupt your care. Plan your visit today.

Hide
Quest Diagnostics

Combination of Plasma Beta Amyloid 42/40 and p-tau217 in the Assessment of Alzheimer’s Disease

AAN 2025

American Academy of Neurology

San Diego, CA, Apr 5-9 , 2025

Oral presentation: Combination of Plasma Beta Amyloid 42/40 and p-tau217 in the Assessment of Alzheimer’s Disease

Authors: Racke MK, Weber DM, Louis J, Stroh M, DeSimone J, Coombes S, Vaillancourt D, Duara R, Smith G, Loewenstein D, Armstrong M, Cid Curiel R, Wang W-E,  Rayaprolu S

Specialty: Neurology

Related content

On-Demand Webinar
Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification
Audio Podcast
Assessing for Alzheimer’s Disease with Quest Diagnostics
Audio Podcast
Alzheimer’s Disease: A New Generation of Screenings and Therapies on the Horizon
Publication
The small HDL particle hypothesis of Alzheimer's disease
Test FAQ
Quest Dementia Testing
On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.